The headline cost of GLP-1 medications, $9001,300/month for brand-name Wegovy or Zepbound, causes many people to give up before they start
The year 2021 witnessed a staggering 529 million diagnosed cases of diabetes, with projections indicating a substantial increase to over 1.31 billion cases by the year 2050 ( GLP-1 RAs are experiencing expanded global utilization and favorable market potential
In some cases, excessive clotting can lead to poor circulation, increasing the risk of thrombosis, heart attack, or stroke
GHK-Cu is proposed to function as a repair-associated signal that may engage fibroblasts, immune cells, enzymes, ion channels, and cell-surface receptors in laboratory models, with copper itself potentially central to collagen formation, inflammatory signaling adjustment, and antioxidant activity in these settings, as noted by Maquart et al
Around 12% of adults have taken a particular category of weight loss peptides called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and combined sales of the most popular GLP-1 RAs have grown by 89% since 2022.1 2 The media has reflected this market expansion, with advertisements for brands like Ozempic and Mounjaro playing in practically every commercial break
Healthcare Lower prevalence of obesity should translate to reduced needs for associated care long-term, altering services required